Last reviewed · How we verify
Sasanlimab Prefilled syringe (sasanlimab-prefilled-syringe)
prefilled syringe
Sasanlimab is a prefilled syringe formulation of a monoclonal antibody that blocks PD-L1, enhancing immune system recognition and destruction of cancer cells. It is approved for specific oncology indications where PD-L1 blockade offers clinical benefit. The prefilled syringe format provides convenience and consistent dosing for patient administration.
At a glance
| Generic name | sasanlimab-prefilled-syringe |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | prefilled syringe |
| Modality | Monoclonal antibody |
| Therapeutic area | Oncology |
| Phase | discontinued |
Mechanism of action
Sasanlimab is an antibody drug that works by targeting a molecular 'off switch' that cancer cells use to escape detection. Normally, cancer cells express a protein called PD-L1 on their surface, which interacts with immune cells and essentially tells them to ignore the cancer. By blocking this interaction, Sasanlimab removes the cancer's protective cloak, making it visible to your immune system again. Once this block is in place, immune cells called T cells can recognize cancer cells as foreign invaders and attack them. This reactivation of the immune system's anti-cancer response is the key mechanism behind how drugs like Sasanlimab work to slow or stop tumor growth. The prefilled syringe format makes administration simpler and more convenient compared to traditional IV infusions, allowing for more flexible treatment scheduling. The effectiveness of Sasanlimab depends on whether your specific cancer expresses sufficient PD-L1 levels, which is why testing is often performed before treatment begins. This targeted approach aims to improve outcomes while potentially having a better side effect profile than broader chemotherapy treatments, though it does activate the immune system in ways that require careful monitoring.
Approved indications
Pipeline indications
- Carcinoma, Non-Small-Cell Lung — discontinued
Common side effects
Key clinical trials
- A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma (discontinued)
- Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced N (discontinued)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sasanlimab Prefilled syringe CI brief — competitive landscape report
- Sasanlimab Prefilled syringe updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI